Clinical Trial Update: Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing PEG-Intron (polyethylene glycol-interferon alfa-2b) to interferon alfa-2b in chronic hepatitis C completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Interferon alfa-2b (interferon alfa-2b)
• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-04-09